1-(4-乙炔基-2-甲氧基苯基)-4-甲基-1H-咪唑 | 1093980-57-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(4-乙炔基-2-甲氧基苯基)-4-甲基-1H-咪唑
• 英文名称: 1-(4-ethynyl-2-methoxyphenyl-4-methyl-1H-imidazole)
• 英文别名: 1-(4-Ethynyl-2-methoxyphenyl)-4-methyl-1h-imidazole；1-(4-ethynyl-2-methoxyphenyl)-4-methylimidazole
• CAS: 1093980-57-4
• 化学式: C₁₃H₁₂N₂O
• 分子量: 212.251
• InChiKey: BLCDRDHCECSGCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-乙炔基-2-甲氧基苯基)-4-甲基-1H-咪唑 在 盐酸 、 copper(II) sulfate 、 sodium ascorbate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 、 1,2-二氯乙烷 、 叔丁醇 为溶剂， 生成
  参考文献：
  名称：

  Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes

  摘要：

  GPR142 has been identified as a potential glucose-stimulated insulin secretion (GSIS) target for the treatment of type 2 diabetes mellitus (T2DM). A class of triazole GPR142 agonists was discovered through a high throughput screen. The lead compound 4 suffered from poor metabolic stability and poor solubility. Lead optimization strategies to improve potency, efficacy, metabolic stability, and solubility are described. This optimization led to compound 20e, which showed significant reduction of glucose excursion in wild-type but not in GPR142 deficient mice in an oral glucose tolerance test (oGTT) study. These studies provide strong evidence that reduction of glucose excursion through treatment with 20e is GPR142-mediated, and GPR142 agonists could be used as a potential treatment for type 2 diabetes.

  DOI：

  10.1021/acsmedchemlett.6b00314
• 作为产物：
  描述：

  3-甲氧基-4-氟苯甲醛 在 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(4-乙炔基-2-甲氧基苯基)-4-甲基-1H-咪唑
  参考文献：
  名称：

  Triazoles as γ-secretase modulators

  摘要：

  Synthesis, SAR, and evaluation of aryl triazoles as novel gamma secretase modulators (GSMs) are presented in this communication. Starting from the literature and in-house leads, we evaluated a range of five-membered heterocycles as replacements for olefins commonly found in non-acid GSMs. 1,2,3-C-aryl-triazoles were identified as suitable replacements which exhibited good modulation of gamma-secretase activity, excellent pharmacokinetics and good central lowering of A beta 42 in Sprague-Dawley rats. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.089

文献信息

• [EN] GAMMA SECRETASE MODULATORS<br/>[FR] MODULATEURS DE LA GAMMA SÉCRÉTASE
  申请人：SCHERING CORP

  公开号：WO2009032277A1

  公开（公告）日：2009-03-12

  This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I).

  这项发明提供了一种调节γ-分泌酶的新化合物。这些化合物的化学式为（I）。还公开了调节γ-分泌酶活性的方法以及使用化合物（I）治疗阿尔茨海默病的方法。
• [EN] GAMMA SECRETASE MODULATORS<br/>[FR] MODULATEURS DE GAMMA SÉCRÉTASE
  申请人：SCHERING CORP

  公开号：WO2010147975A1

  公开（公告）日：2010-12-23

  This invention provides novel compounds that are modulators of gamma secretase. The compounds have the Formula I: Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of Formula I.

  这项发明提供了一种调节γ-分泌酶的新型化合物。这些化合物具有公式I：还公开了调节γ-分泌酶活性的方法以及使用公式I化合物治疗阿尔茨海默病的方法。
• GAMMA SECRETASE MODULATORS
  申请人：Zhu Zhaoning

  公开号：US20120238546A1

  公开（公告）日：2012-09-20

  This invention provides novel compounds that are modulators of gamma secretase. The compounds have the Formula (I): Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of Formula (I).

  这项发明提供了一种新型化合物，它们是γ-分泌酶的调节剂。这些化合物的化学式为（I）：还公开了调节γ-分泌酶活性的方法以及使用化合物（I）治疗阿尔茨海默病的方法。
• TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS
  申请人：Fischer Christian

  公开号：US20100222320A1

  公开（公告）日：2010-09-02

  Compounds of formula I: Selectively attenuate production of Aβ(1-42) and hence find use in treatment or prevention of diseases associated with deposition of Aβ in the brain, in particular Alzheimer's disease.

  公式为I的化合物：选择性地减弱Aβ（1-42）的产生，因此可用于治疗或预防与Aβ在大脑中沉积相关的疾病，特别是阿尔茨海默病。
• Triazole derivatives for treating alzheimer'S disease and related conditions
  申请人：Merck Sharp & Dohme Corp.

  公开号：US08242150B2

  公开（公告）日：2012-08-14

  Compounds of formula I: Selectively attenuate production of Aβ(1-42) and hence find use in treatment or prevention of diseases associated with deposition of Aβ in the brain, in particular Alzheimer's disease.

  化合物I的公式：选择性地减弱Aβ（1-42）的产生，因此可用于治疗或预防与Aβ在大脑沉积有关的疾病，特别是阿尔茨海默病。